Member Info for amones

Jatw,
Last sentence from your earlier post, “... There is a second PIPE transaction at a higher price”. Can you please explain what this PIPE transaction is? Thanks

Cheerleader in chief! He certainly is! (Not sure about the holiday as found to be active on other Company share chats)

Thanks Jatw, your post is a well balanced description of the present state of the prospects of the company. Many of us, the long timers, have withstood the ups and Downs. We rightly deserve a small return if not a reward.

After 18 months of traumatic period, sp has raisen above £5. Superb recovery so far. Almost doubled since mid March! In spite of the prevailing geopolitical situations, recovery at NYSE has been remarkable. Undoubtedly, there should be strong reason/s for what we are witnessing. Is it just the recent re-marking by the analysts? Or, impending news about Savolitinib (+ Tagrisso)/Surufatinib/? HK listing?
This board remains not so excited and the board on other site totally silent!!
Any guesses about the peak this time around?
Davey, you first, please!

There are far too many different positive reasons to hold. This is my personal opinion.

BB, Thanks for explaining. Useful information.
Being a naive individual investor, I could not understand if yesterday’s news was significant or not. I saw other posters mentioning it as wonderful. Hence, I posted my query. Yesterday’s uptick in NYSE could be due to various factors.

As usual LSE AIM market is oblivious to it. Wish our CEO had given a short statement about this item. Is it a good news for the company? We shall know in few hours time how the NYSE treats it as.

Can not understand this pre condition “Prove commercialisation success” first before listing in Hong Kong? Is it a criteria for biotechs listing over there? Or, is it just self imposed?

Hi ttyn,
Welcome to the board. The link you provided has been removed, probably by lse. Matter of HK listing has been mentioned on numerous occasions. Did you see that news as a fresh item? ADRs at NYSE are exchanging hands at $32 a piece. Some relief!

Still surging!! $31.25.
Not seen this kind of market response recently.
Is it Surufatinib related??

That’s great news! Thanks Jatw.
Is GA going in with another investment? Or, Any imminent news about Surufatinib for Neuroendocrine malignancy?

Davey, I appreciate your posts and research about this company over the last several years. Many times you too have expressed disappointment about the lack of market response to all the great achievements from the research and development side. End of 2017, SP was equal to £5.90. In spite of all the good news coming out since 2017, the SP is sub £4.50.
Agreed, CKHH’s botched placement was a major blow. But, what about other issues? When was the last time we read about the directors buying in big numbers ? Why is it still listed on the ‘not so standard’ AIM? Is it not a matter of concern for all the lon timers? When are we getting moved to the main LSE board? While so many new biotech companies are getting listed at HK exchange, why this company with such credentials is not open to investors from China and HK?

Let’s feel happy about the way SP has risen during last two trading days? Is it GA investing again or some positive news about Surufatinib in USA?

Both Tacly and Jatw are spot on with their opinions and analysis. Management does not seem to have any interest in improving shareholder value. Sorry to write this. Even during last week’s financial presentation, nothing was mentioned in that respect.
Investors who bought these shares more than 10 years ago, might have some paper profit. But, it is not the case for shares bought for £4-5.
The company doesn’t seem to make any effort to migrate from AIM listing to the main LSE. This minor effort itself can bring a large number of UK institutional investors. In addition, institutional as well as private investors from China (?Hong Kong as well) will be able to invest in HCM through the ‘LSE-SHANGHAI stock market link’. This was discussed on numerous occasions on this board. Last year, I wrote to the company asking if they have looked at this opportunity. The CEO answered back saying the company was very much aware of that new aspect. But, nothing seems to be happening. We keep asking this repeatedly, Why is the company not allowing investors from the second largest economy in the world to invest in a China based company?
Yes, it is a very good company with a fantastic research and development wing and great oncology therapeutic products. But, without any prospects of improvement in shareholder value in the near future, is it wise to buy anymore of these shares? What would happen in case of dilution?

Before investing $100 million, managers of GA must have done their research and homework. We can only hope their timing of investment has been perfect. Glad to see share price steadily improving. Though it is a long way to go before reaching the heights of 2017.
JatW, totally agree, FTSE 250 is the correct place for this stock. By doing so, it would allow few British (?as well China based) fund managers to do what GA has done across the pond. Somebody should whisper to CH, he is too good to work for an AIM listed company! (Get a promotion by moving your company to the main listing on LSE).
GLA long timers and new comers!

Davey, regarding your concern about rolling out Surufatinib in the USA. I watched CEO’s CNBC interview. While answering the question about ‘China’ factor, he sounded confident and realistic. I think he mentioned about USA having no effective therapeutic agents available to treat patients diagnosed with Neuroendocrine tumours. When it is about people suffering from cancer, no geopolitical issue should intervene while making it possible for the clinicians to access an evidence based therapy. We shall hope to hear some good news about marketing strategies not just in the US, but, all over the world.
Sincerely wishing for Surufatinib to be helpful to all Oncologists caring for people diagnosed with Neuroendocrine tumours. Surely, it will be a satisfying reward to all the researchers and scientists at Chi-med.

Davey, Thank you for sharing this news. $95 millions appears a good sum for a company of this size. Do you remember the sum involved in the earlier land compensation paid to the company, few years ago?

The share price of this company fails to reach the average levels of 2018/19 (if not higher than) even after all these ‘great‘ news releases. Not sure, what else is expected of this company to increase its market value.
Hence, not at all a comfortable feeling to all longtime investors. Does it not bother the directors? Few of them continue to hold significant numbers of shares.

Now a days, share price is a third less than the end of 2018 prices. All these ‘good news’ about company’s products doesn’t seem to have any effect on the sp.

The simple reason for the ‘lack of interest’ for HCM shares in the UK is that HCM is not listed on the main market of LSE. Unless its moved to the main market, many institutional investors and fund managers can not invest in HCM due to ?self imposed restrictions. This has been discussed here many times.

Another benefit of listing on the main market: It will allow investors from China and HK to invest in HCM through the LONDON-SHANGHAI stock exchanges link. (HCM being an AIM listed company, China and HK based investors can not buy HCM at present).

Is it not worth trying?

News item today ‘... no new cases reported today in China’.
Is it better to ‘migrate’ to safer places??

If the same $110 million were to be raised at HK, following (long awaited) listing over there, both share price and market valuation would have appeared much more healthier.